Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1982 Sep;46(3):397–402. doi: 10.1038/bjc.1982.216

Effects of cisplatin on different haemopoietic progenitor cells in mice.

M R Nowrousian, C G Schmidt
PMCID: PMC2011135  PMID: 6889884

Abstract

The effects of Cisplatin on marrow haemopoietic progenitor cells, WBC and RBC were measured and compared in F1 (CBA x C57BL) female mice. Dose/survival curves of Cisplatin for CFU-S, CFU-C and BFU-E were found to be simply exponential, indicating that the effect of the drug has no cell-cycle dependency. BFU-E also appeared significantly (P less than 0.001) more sensitive to Cisplatin than CFU-S and CFU-C. After a single dose of 12 mg/kg of Cisplatin, WBC, MNC and CFU-E were seen to be markedly less reduced and to recover much earlier than CFU-C, and particularly BFU-E and CFU-S. Results suggest that the drug is more toxic for earlier haemopoietic progenitor cells than for the more mature cells, and that the latter are not reliable parameters for complete haemopoietic recovery in mice after treatment with this agent. In the animals treated, there was also a subsequent significant decrease of the RBC count, accompanied by a marked increase of the marrow CFU-E concentration. Possible underlying mechanisms (e.g. alterations of RBC after exposure to Cisplatin) were discussed.

Full text

PDF
397

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Botnick L. E., Hannon E. C., Vigneulle R., Hellman S. Differential effects of cytotoxic agents on hematopoietic progenitors. Cancer Res. 1981 Jun;41(6):2338–2342. [PubMed] [Google Scholar]
  2. Bradley T. R., Metcalf D. The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci. 1966 Jun;44(3):287–299. doi: 10.1038/icb.1966.28. [DOI] [PubMed] [Google Scholar]
  3. Byrne P. V., Heit W., Kubanek B. Stimulation of in vitro granulocyte--macrophage colony formation by mouse heart conditioned medium. Br J Haematol. 1978 Oct;40(2):197–204. doi: 10.1111/j.1365-2141.1978.tb03657.x. [DOI] [PubMed] [Google Scholar]
  4. Chary K. K., Higby D. J., Henderson E. S., Swinerton K. D. Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treat Rep. 1977 May-Jun;61(3):367–370. [PubMed] [Google Scholar]
  5. Drewinko B., Brown B. W., Gottlieb J. A. The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res. 1973 Dec;33(12):3091–3095. [PubMed] [Google Scholar]
  6. Freireich E. J., Gehan E. A., Rall D. P., Schmidt L. H., Skipper H. E. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep. 1966 May;50(4):219–244. [PubMed] [Google Scholar]
  7. Gallicchio V. S., Murphy M. J., Jr In vitro erythropoiesis. II. Cytochemical enumeration of erythroid stem cells (CFU-e and BFU-e) from normal mouse and human hematopoietic tissues. Exp Hematol. 1979 May;7(5):219–224. [PubMed] [Google Scholar]
  8. Getaz E. P., Beckley S., Fitzpatrick J., Dozier A. Cisplatin-induced hemolysis. N Engl J Med. 1980 Feb 7;302(6):334–335. doi: 10.1056/NEJM198002073020607. [DOI] [PubMed] [Google Scholar]
  9. Guzman E., Lajtha L. G. Some comparisons of the kinetic properties of femoral and splenic haemopoietic stem cells. Cell Tissue Kinet. 1970 Apr;3(2):91–98. doi: 10.1111/j.1365-2184.1970.tb00257.x. [DOI] [PubMed] [Google Scholar]
  10. Hara H., Ogawa M. Erythropoietic precursors in mice under erythropoietic stimulation and suppression. Exp Hematol. 1977 Mar;5(2):141–148. [PubMed] [Google Scholar]
  11. Iscove N. N., Sieber F. Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture. Exp Hematol. 1975 Jan;3(1):32–43. [PubMed] [Google Scholar]
  12. Jenkins V. K., Perry R. R., Goodrich W. E. Effects of Cis-diamminedichloroplatinum (II) on hematopoietic stem cells in mice. Exp Hematol. 1981 Mar;9(3):281–287. [PubMed] [Google Scholar]
  13. Krakoff I. H. Nephrotoxicity of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1523–1525. [PubMed] [Google Scholar]
  14. Kuzur M. E., Greco F. A. Cisplatin-induced anemia. N Engl J Med. 1980 Jul 10;303(2):110–111. doi: 10.1056/NEJM198007103030215. [DOI] [PubMed] [Google Scholar]
  15. Levi J. A., Aroney R. S., Dalley D. N. Haemolytic anaemia after cisplatin treatment. Br Med J (Clin Res Ed) 1981 Jun 20;282(6281):2003–2004. doi: 10.1136/bmj.282.6281.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nguyen B. V., Jaffe N., Lichtiger B. Cisplatin-induced anemia. Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1121–1121. [PubMed] [Google Scholar]
  17. Ogawa M., Gale G. R., Keirn S. S. Effects of cis-diamminedichloroplatinum (NSC 119875) on murine and human hemopoietic precursor cells. Cancer Res. 1975 Jun;35(6):1398–1401. [PubMed] [Google Scholar]
  18. Penta J. S., Rozencweig M., Guarino A. M., Muggia F. M. Mouse and large-animal toxicology studies of twelve antitumor agents: relevance to starting dose for phase I clinical trials. Cancer Chemother Pharmacol. 1979;3(2):97–101. doi: 10.1007/BF00254979. [DOI] [PubMed] [Google Scholar]
  19. Peschle C., Migliaccio G., Lettieri F., Migliaccio A. R., Ceccarelli R., Barba P., Titti F., Rossi G. B. Kinetics of erythroid precursors in mice infected with the anemic or the polycythemic strain of Friend leukemia virus. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2054–2058. doi: 10.1073/pnas.77.4.2054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rossof A. H., Slayton R. E., Perlia C. P. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP). Cancer. 1972 Dec;30(6):1451–1456. doi: 10.1002/1097-0142(197212)30:6<1451::aid-cncr2820300606>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  21. Rothmann S. A., Weick J. K. Cisplatin toxicity for erythroid precursors. N Engl J Med. 1981 Feb 5;304(6):360–360. doi: 10.1056/NEJM198102053040617. [DOI] [PubMed] [Google Scholar]
  22. TILL J. E., McCULLOCH E. A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res. 1961 Feb;14:213–222. [PubMed] [Google Scholar]
  23. Talley R. W., O'Bryan R. M., Gutterman J. U., Brownlee R. W., McCredie K. B. Clinical evaluation of toxic effects of cis-diamminedichloroplatinum (NSC-119875)--phase I clinical study. Cancer Chemother Rep. 1973 Nov-Dec;57(4):465–471. [PubMed] [Google Scholar]
  24. Testa N. G. Erythroid progenitor cells: their relevance for the study of haematological disease. Clin Haematol. 1979 Jun;8(2):311–333. [PubMed] [Google Scholar]
  25. Valeriote F. A., Collins D. C., Bruce W. R. Hematological recovery in the mouse following single doses of gamma radiation and cyclophosphamide. Radiat Res. 1968 Mar;33(3):501–511. [PubMed] [Google Scholar]
  26. Van Putten L. M., Lelieveld P., Kram-Idsenga L. K. Cell-cycle specificity and therapeutic effectiveness of cytostatic agents. Cancer Chemother Rep. 1972 Dec;56(6):691–700. [PubMed] [Google Scholar]
  27. Von Hoff D. D., Schilsky R., Reichert C. M., Reddick R. L., Rozencweig M., Young R. C., Muggia F. M. Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1527–1531. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES